MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231 Covering Treatment of Diabetes with MANF Allowed claims
March 01 2018 - 6:00AM
InvestorsHub NewsWire
MANF Therapeutics
Announces the Issuance of U.S.
Patent #9,891,231
Covering
Treatment of Diabetes
with MANF
- Allowed claims include the treatment of Type 1 and
Type 2 Diabetes
- Patent protects
exclusivity for MANF in diabetes in the
US into 2032
San Francisco, CA -- March 01, 2018 -- InvestorsHub
NewsWire -- MANF Therapeutics, a wholly-owned subsidiary
of Amarantus
Bioscience Holdings, Inc. (OTCPK:
AMBS), a US-based biotechnology
holding
company
with subsidiaries
developing first-in-class orphan
neurologic, regenerative medicine
and
ophthalmic therapies, today announced that the US Patent &
Trademark Office has issued US Patent #9,891,231 covering the use of mesencephalic
astrocyte-derived neurotrophic factor (MANF) as a treatment for
beta cell disorders, including Type-1 and Type-2 diabetes. This
patent extends exclusivity for MANF in the treatment of diabetes in
the US into 2032. There is
strong belief that MANF has significant
therapeutic potential across multiple orphan disease
areas, as well
as in large indications such as diabetes and cardiovascular
disease. MANF Therapeutics is preparing to restart
IND-enabling development of MANF in
2018 in
glaucoma and retinitis pigmentosa, an indication for
which MANF has received orphan drug designation.
Multiple
research groups have published data demonstrating the therapeutic
potential of MANF in treating diabetes, including data published in
the peer-reviewed scientific journal Cell Reports entitled
"MANF Is
Indispensable for the Proliferation and Survival of Pancreatic
Cells."
That study demonstrated the therapeutic
benefit of MANF in protecting and restoring
pancreatic beta
cells in vitro and in vivo
in
animal
models of diabetes. The study's authors determined "lack of MANF
in vivo in mouse leads to chronic
unfolded protein response (UPR) activation in pancreatic islets.
Importantly, MANF protein enhanced cell proliferation
in vitro and overexpression of
MANF in the pancreas of diabetic mice enhanced cell regeneration.
We demonstrate that MANF specifically promotes cell proliferation
and survival, thereby constituting a therapeutic candidate for cell
protection and regeneration."
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings
(AMBS) is a biotechnology company developing treatments and
diagnostics for diseases in the areas of neurology, regenerative
medicine and orphan diseases through its subsidiaries. AMBS'
wholly-owned subsidiary Elto Pharma, Inc. has development rights to
eltoprazine, a Phase 2b-ready small molecule indicated for
Parkinson's disease levodopa-induced dyskinesia, Alzheimer's
aggression and adult attention deficit hyperactivity disorder,
commonly known as ADHD. AMBS acquired the rights to the Engineered
Skin Substitute program (ESS), a regenerative medicine-based
approach for treating severe burns with full-thickness autologous
skin grown in tissue culture that is being pursued by AMBS'
wholly-owned subsidiary Cutanogen
Corporation.
AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key
intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor ("MANF"). MANF Therapeutics, Inc.
is developing
MANF-based products as treatments for brain and ophthalmic
disorders. MANF was discovered by the Company's Chief Scientific
Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from
AMBS' proprietary discovery engine PhenoGuard. AMBS also owns
approximately 79.25 million shares of Avant
Diagnostics, Inc. via the sale of its wholly-owned subsidiary
Amarantus Diagnostics, Inc. that occurred in May 2016.
For further information please
visit www.Amarantus.com, or connect with the
Amarantus on Facebook, LinkedIn, Twitter and Google+.
About MANF
Therapeutics, Inc.
MANF
(mesencephalic-astrocyte-derived neurotrophic factor) is believed
to have broad potential because it is a naturally-occurring protein
produced by the body to reduce/prevent
apoptosis (cell
death) in response to injury or disease, via the unfolded protein
response. By administering exogenously produced
MANF the
body, Amarantus is seeking to use a regenerative medicine approach
to assist the body with higher quantities of MANF when needed.
Amarantus is the front-runner and primary holder of intellectual
property around MANF, and is initially focusing on the development
of MANF-based protein therapeutics.
MANF's lead indication is
retinitis pigmentosa, and additional indications including
Parkinson's disease, diabetes and Wolfram's syndrome are
envisioned.
Further applications for MANF may include Alzheimer's disease,
traumatic brain injury, myocardial infarction, antibiotic-induced
ototoxicity
and certain other orphan diseases.
In April 2017, Amarantus
incorporated the wholly-owned subsidiary MANF Therapeutics, Inc. to
focus on progressing preclinical and clinical development of
MANF.
Forward-Looking
Statements
Certain statements, other than
purely historical information, including estimates, projections,
statements relating to our business plans, objectives, and expected
operating results, and the assumptions upon which those statements
are based, are forward-looking statements. These forward-looking
statements generally are identified by the words "believes,"
"project," "expects," "anticipates," "estimates," "intends,"
"strategy," "plan," "may," "will," "would," "will be," "will
continue," "will likely result," and similar expressions.
Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may
cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect
of future
plans or
strategies is inherently uncertain. Factors which could have a
material adverse effect on our operations and future prospects on a
consolidated basis include, but
are not limited to:
changes in economic conditions, legislative/regulatory changes,
availability of capital, interest rates, competition, and generally
accepted accounting principles. These risks and uncertainties
should also be considered in evaluating forward-looking statements
and undue reliance should not be placed on such
statements.
Amarantus
Investor and Media Contact:
Ascendant Partners,
LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience
Holdings, Inc.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024